|Day Low/High||55.80 / 59.43|
|52 Wk Low/High||32.95 / 64.48|
Let's see what the charts suggest for risk points.
The S&P 500 has shown the same pattern for three consecutive days.
The best way to deal with it is to keep on hunting for individual stocks.
It is two totally different markets when you compare the small-cap action to the big-cap indices.
We are seeing a focus on finding smaller names that may offer interesting valuations and stories.
This underperformance is being caused by pockets of weakness in bigger-cap names.
The key for the overall market now is that it hold above today's early lows.
There is no question that we are becoming extended and ripe for some profit taking.
Sector charts should shape up as worries about prices are finally put to rest.
Overall it is still a positive day but the action is sloppy.
Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.
The challenge of this market is that the upward moves have not been well sustained.
Rotational action is the main theme Wednesday and good opportunities are out there.
There's a worrisome scenario that could develop this afternoon.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
Obesity costs are a pain point, which often create good investments.
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.
Adam Feuerstein, Sr. Columnist for TheStreet, is assembling candidates for the Best Biotech CEO of 2012 award.
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.
Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.